Now showing items 1-4 of 4

    • Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas. 

      López-Knowles, E; Gao, Q; Cheang, MCU; Morden, J; Parker, J; Martin, L-A; Pinhel, I; McNeill, F; Hills, M; Detre, S; Afentakis, M; Zabaglo, L; Dodson, A; Skene, A; Holcombe, C; Robertson, J; Smith, I; Bliss, JM; Dowsett, M; POETIC trialists (2016-04)
      <h4>Background</h4>Gene expression is widely used for the characterisation of breast cancers. Variability due to tissue heterogeneity or measurement error or systematic change due to peri-surgical procedures can affect ...
    • Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation. 

      Gellert, P; Segal, CV; Gao, Q; López-Knowles, E; Martin, L-A; Dodson, A; Li, T; Miller, CA; Lu, C; Mardis, ER; Gillman, A; Morden, J; Graf, M; Sidhu, K; Evans, A; Shere, M; Holcombe, C; McIntosh, SA; Bundred, N; Skene, A; Maxwell, W; Robertson, J; Bliss, JM; Smith, I; Dowsett, M; POETIC Trial Management Group and Trialists (2016-11-09)
      Pre-surgical studies allow study of the relationship between mutations and response of oestrogen receptor-positive (ER+) breast cancer to aromatase inhibitors (AIs) but have been limited to small biopsies. Here in phase I ...
    • Major Impact of Sampling Methodology on Gene Expression in Estrogen Receptor-Positive Breast Cancer. 

      Gao, Q; López-Knowles, E; U Cheang, MC; Morden, J; Ribas, R; Sidhu, K; Evans, D; Martins, V; Dodson, A; Skene, A; Holcombe, C; Mallon, E; Evans, A; Bliss, JM; Robertson, J; Smith, I; Martin, L-A; Dowsett, M; POETIC Trial Management Group and Trialists (2018-04)
      To investigate the impact of sampling methodology on gene expression data from primary estrogen receptor-positive (ER+) breast cancer biopsies, global gene expression was measured in core-cut biopsies at baseline and surgery ...
    • Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations. 

      Lopez-Knowles, E; Pearson, A; Schuster, G; Gellert, P; Ribas, R; Yeo, B; Cutts, R; Buus, R; Garcia-Murillas, I; Haynes, B; Martin, L-A; Smith, I; Turner, N; Dowsett, M (2019-01)
      BACKGROUND:Several thousand breast cancer patients develop resistance to aromatase inhibitors (AIs) each year in the UK. Rational treatment requires an improved molecular characterisation of resistant disease. MATERIALS ...